The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.
Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:
Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.
We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.
More top news
The ISIS execution gang fronted by 'Jihadi John' had two British extremists who learned radical Islam together in London, ITV News reveals.
Today started quite promising for many, largely dry and sunny.
Turkish deputy premier says 15,000 refugees from Syria have been admitted with a further 30,000 refugees being cared for across the border